Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Joel M. Trugman

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial

Headache

Neurology

2020

English

Caffeine and Progression of Parkinson Disease

Clinical Neuropharmacology

Neurology

Pharmacology

2008

English

Related publications

P.010 Efficacy, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine: A Single-Attack Phase 3 Study, ACHIEVE II

Canadian Journal of Neurological Sciences

Medicine

Neurology

2019

English

Long-Term Efficacy and Safety of Brodalumab in the Treatment of Psoriasis: 120-Week Results From the Randomized, Double-Blind, Placebo- And Active Comparator–controlled Phase 3 AMAGINE-2 Trial

Journal of the American Academy of Dermatology

Dermatology

2020

English

Intravenous Immunoglobulin for Maintenance Treatment of Multifocal Motor Neuropathy: A Multicenter, Open-Label, 52-Week Phase 3 Trial

Journal of the Peripheral Nervous System

English

Pd50-06 Long-Term Safety and Tolerability of Oral Testosterone (Lpcn 1021) in Hypogonadal Men: Results From the 52-Week Phase 3 Study

Journal of Urology

Urology

2016

English

Adalimumab for Nail Psoriasis: Efficacy and Safety Over 52 Weeks From a Phase‐3, Randomized, Placebo‐Controlled Trial

Journal of the European Academy of Dermatology and Venereology

Dermatology

Infectious Diseases

2019

English

Long-Term Effects of Fingolimod in Multiple Sclerosis: The Randomized FREEDOMS Extension Trial

Neurology

2015

English

Adalimumab for Nail Psoriasis: Efficacy and Safety From the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial

SKIN The Journal of Cutaneous Medicine

2017

English

Longterm (52-Week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients With Psoriatic Arthritis

Journal of Rheumatology

English

Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results From 2 Randomized Phase-Iii Studies and 1 Open-Label Long-Term Extension Study

Journal of the American Academy of Dermatology

Dermatology

2016

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Joel M. Trugman

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial

Caffeine and Progression of Parkinson Disease

Related publications

P.010 Efficacy, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine: A Single-Attack Phase 3 Study, ACHIEVE II

Long-Term Efficacy and Safety of Brodalumab in the Treatment of Psoriasis: 120-Week Results From the Randomized, Double-Blind, Placebo- And Active Comparator–controlled Phase 3 AMAGINE-2 Trial

Intravenous Immunoglobulin for Maintenance Treatment of Multifocal Motor Neuropathy: A Multicenter, Open-Label, 52-Week Phase 3 Trial

Pd50-06 Long-Term Safety and Tolerability of Oral Testosterone (Lpcn 1021) in Hypogonadal Men: Results From the 52-Week Phase 3 Study

Adalimumab for Nail Psoriasis: Efficacy and Safety Over 52 Weeks From a Phase‐3, Randomized, Placebo‐Controlled Trial

Long-Term Effects of Fingolimod in Multiple Sclerosis: The Randomized FREEDOMS Extension Trial

Adalimumab for Nail Psoriasis: Efficacy and Safety From the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial

Longterm (52-Week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients With Psoriatic Arthritis

Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results From 2 Randomized Phase-Iii Studies and 1 Open-Label Long-Term Extension Study